Therapy of intracellular Staphylococcus aureus by tigecyclin

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Kreis, Carolin A ^a   Raschke, Michael J ^a   Roßlenbroich, Steffen B ^a   Tholema Hans, Nancy ^a   Löffler, Bettina ^a   Fuchs, Thomas ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Biomechanical stability; Implant associated infection; Osteomyelitis; Staphylococcus aureus; Tigecyclin

Indexed keywords

BONE CEMENT; GENTAMICIN; POLY(METHYL METHACRYLATE); RIFAMPICIN; TIGECYCLINE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BIOMECHANICS; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR BACTERIUM; OSTEOBLAST; OSTEOMYELITIS; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BIOMECHANICAL PHENOMENA; BONE CEMENTS; CELLS, CULTURED; HUMANS; INTRACELLULAR SPACE; MATERIALS TESTING; MINOCYCLINE; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOMYELITIS; PROSTHESIS-RELATED INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84878452446     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-267     Document Type: Article

References (42)

1. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004, 364:369-379. 10.1016/S0140-6736(04)16727-5, 15276398.
2. Ellington JK, Harris M, Hudson MC, et al. Intracellular Staphylococcus Aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis. J Orthop Res 2006, 24:87-93. 10.1002/jor.20003, 16419973.
3. Ciampolini J, Harding KG. Pathophysiology of chronic bacterial osteomyelitis. why do antibiotics fail so often?. Postgrad Med J 2000, 76:479-483. 10.1136/pmj.76.898.479, 1741709, 10908375.
4. Hellmark B, Unemo M, Nilsdotter-Augustinsson A, Söderquist B, et al. Antibiotic susceptibility among staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene. Clin Microbiol Infect 2009, 15:238-244. 10.1111/j.1469-0691.2008.02663.x, 19196261.
5. Seligson D, Klemm K. Adult posttraumatic osteomyelitis of the tibial diaphysis of the tibial shaft. Clin Orthop Relat Res 1999, 360:30-36.
6. Buchholz HW, Elson RA, Engelbrecht E, et al. Management of deep infection of total hip replacement. J Bone Joint Surg Br 1981, 63-B(3):342-353.
7. Trampuz A, Zimmerli W. Prosthetic joint infections: update in diagnosis and treatment. Swiss Med Wkly 2005, 135(17-18):243-252.
8. Proctor RA, von Eiff C, Kahl BC, et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 2006, 4:295-305. 10.1038/nrmicro1384, 16541137.
9. von Eiff C, Peters G, Becker K. The small colony variant (SCV) concept - the role of staphylococcal SCVs in persistent infections. Injury 2006, 37:526-533.
10. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001, 358(9276):135-138. 10.1016/S0140-6736(01)05321-1, 11463434.
11. Tang H, Xu Y. Bacterial biofilms and chronic osteomyelitis. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2010, 24(1):108-111.
12. Breusch SJ, Kühn KD. Knochenzemente auf basis von polymethylmethacrylat. Orthopade 2003, 32:41-50. 10.1007/s00132-002-0411-0, 12557085.
13. Henry SL, Galloway KP. Local antibacterial therapy for the management of orthopaedic infections. Pharmacokinet considerations. Clin Pharmacokinet. 1995, 29(1):36-45.
14. Raschke MJ, Schmidmaier G. Biological coating of implants in trauma and orthopedic surgery. Unfallchirurg 2004, 107(8):653-663.
15. Reichert P, Rutowski R, Gosk J. Application of gentamycini impregnated polymethylmethacrylate (PMMA) (Septopal) in treatment of infected nonunion. Own exp. Polim Med. 2007, 37(4):65-72.
16. Anguita-Alonso P, Hanssen AD, Osmon DR, et al. High rate of aminoglycoside resistance among staphylococci causing prosthetic joint infection. Clin Orthop Relat Res 2005, 439:43-47. 10.1097/01.blo.0000182394.39601.9d, 16205136.
17. Neut D, Kluin OS, Crielaard BJ, et al. A biodegradable antibiotic delivery system based on poly- (trimethylene carbonate) for the treatment of osteomyelitis. Acta Orthop 2009, 80(5):514-519. 10.3109/17453670903350040, 2823332, 19916681.
18. Anguita-Alonso P, Rouse MS, Piper KE, et al. Comparative study of antimicobial release kinetics from polymethylmethacrylate. Clin Orthop Relat Res 2006, 445:239-244.
19. van de Belt H, Neut D, Schenk W, et al. Staphylococcus aureus biofilm formation on different gentamicin-loaded polymethylmethacrylate bone cements. Biomaterials 2001, 22(12):1607-1611. 10.1016/S0142-9612(00)00313-6, 11374461.
20. Chang CC, Merritt K. Infection at the site of implanted materials with and without preadhered bacteria. J Orthop Res 1994, 12(4):526-531. 10.1002/jor.1100120409, 8064483.
21. Chang CC, Merritt K. Microbial adherence on poly(methyl methacrylate) (PMMA) surfaces. J Biomed Mater Res 1992, 26(2):197-207. 10.1002/jbm.820260206, 1569113.
22. Barton E, MacGowan A. Future treatment options for gram-positive infections - looking ahead. Clin Micobiol. Infect. 2009, 6:17-25.
23. Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 2006, 26(8):1099-1110. 10.1592/phco.26.8.1099, 16863487.
24. Hawkey P, Finch R. Tigecycline: in-vitro performance as a predictor of clinical efficacy. Clin Microbio Infect 2007, 13:354-362.
25. Verkade EJ, Verhulst CJ, Huijsdens XW, Kluytmans JA. In vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated strains. Eur J Clin Microbiol Infect Dis 2010, 29(5):503-507. 10.1007/s10096-010-0886-2, 2854363, 20186450.
26. Aslam S. Effect of antibacterials on biofilms. J of Infect Control 2008, 36:S175 e9-S175 e11.
27. Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100mg dose. J Antimicrob Chemother 2006, 58(6):1221-1229. 10.1093/jac/dkl403, 17012300.
28. Anstead GM, Quinones-Nazario G, Lewis JS. Treatment of infections caused by resistant Staphylococcus aureus. Methods Mol Biol 2007, 391:227-258. 10.1007/978-1-59745-468-1_17, 18025681.
29. Haslinger-Loeffler B, Kahl BC. Multiple virulence factors are required for Staphylococcus aureus-induced apoptosis in endothelial cells. cellular microbiology. Grundmeier Met al 2005, 7(8):1087-1097.
30. Duez JM, Adochitei A, Péchinot A, et al. In vitro combinations of five intravenous antibiotics with dalfopristin-quinupristin against Staphylococcus aureus in a 3-dimensional model. J Chemother 2008, 20(6):684-689.
31. Demczar DJ, Nafziger AN, Beritino JS. Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother 1997, 5:115-119.
32. EUCAST Technical note on tigecycline. Clin Microbiol Infect 2006, 12:1147-1149. EUCAST.
33. Roth B. Penetration of parenterally administered rifampicin into bone tissue. Chemotherapy 1984, 30(6):358-365. 10.1159/000238294, 6518835.
34. Sandberg A, Hessler JHR, Skov RL, et al. Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. Antimicrob Agents Chemother 2009, 53(5):1874-1883. 10.1128/AAC.01605-07, 2681564, 19223616.
35. Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents 2009, 34(8):1-9.
36. Yin LY, Lazzarini L, Li F, et al. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 2005, 55:995-1002. 10.1093/jac/dki109, 15857944.
37. Trampuz A, Zimmerli W. Antimicrobial agents in orthopaedic surgery: prophylaxis and treatment. Drugs 2006, 66(8):1089-1105. 10.2165/00003495-200666080-00005, 16789794.
38. Seldes RM, Winiarsky R, Jordan LC, et al. Liqiud gentamicin in bone cement: a laboratory study of a potentially more cost-effective cement spacer. L Bone Joint Surg 2005, 87:268-272.
39. Kandemir O, Oztuna V, Colak M, et al. Comparison of the efficacy of tigecycline and teicoplanin in an experimental methicillin-resistant Staphylococcus aureus osteomyelitis model. J Chemother 2008, 20(1):53-57.
40. Smith K, Gould KA, Ramage G, et al. Influence of tigecycline an expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2010, 380-387.
41. Grossi PA. Early appropiate therapy of Gram-positive bloodstream infections: the conservative use of new drugs. Int J of Antimicrob Agents 2009, 34S:S31-S34.
42. Rose WE, Poppens PT. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J Antimicrob Chemother 2009, 63:485-488. 10.1093/jac/dkn513, 19109338.